Hims & Hers Health Reports Strong Profit but Misses Revenue Estimates in Q2 2025

Aug 4, 2025

Hims & Hers Health announced its financial results for the second quarter of 2025, showing a profit that beat Wall Street expectations. The company attributes its improved profit to steady growth in subscriptions and higher demand for its telehealth weight-loss services.

Despite the profit beat, Hims & Hers Health reported quarterly revenue of $544.8 million, a 73% increase compared to the previous year. However, this figure was below what Wall Street analysts had expected, leading to a drop in the company’s share price during after-hours trading.

The company maintained its forecast for full-year results, but its outlook for the third quarter was lower than what analysts had anticipated. Investors will be watching to see if Hims & Hers can continue its growth in upcoming quarters.

Why did Hims & Hers stock fall even though it beat profit expectations?

The stock fell because the company missed Wall Street’s revenue expectations and gave a third-quarter forecast lower than analysts expected.

What helped Hims & Hers improve its profits?

Steady growth in subscriptions and higher demand for its weight-loss telehealth services helped boost profits.

Did the company change its forecast for the rest of the year?

No, Hims & Hers kept its full-year outlook unchanged.

Sources
Hims and Hers beats quarterly profit on steady subscription growth
Reuters
Hims and Hers Health beat Wall Street estimates for second-quarter profit on Monday, aided by continued subscription growth and surging volume in the telehealth company's weight-loss business.
Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results
Business Wire
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. “It's never bee...
Hims & Hers stock falls 10% on revenue miss
CNBC
Hims & Hers Health shares fell in extended trading after the company reported second-quarter results that missed Wall Street's expectations for revenue. Revenue increased 73% year over year to $544.8 million.
Hims & Hers sees ‘an exciting period of growth,' but stock falls
Market Watch
Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform's third-quarter forecast came up shy of Wall Street's estimates, although the company stuck with its full-year outlook.
Him & Hers Health report Q2 earnings, missing revenue estimates
CNBC Television
CNBC's Brandon Gomez reports on Hims & Hers Health's latest earnings report.
Hims & Hers (HIMS) Q2 Revenue Jumps 73%
The Motley Fool
Hims & Hers Health (HIMS 1.38%), a direct-to-consumer digital health platform focusing on telehealth, subscription medications, and personalized care, released its second quarter 2025 results on August 4, 2025. The headline news: GAAP revenue grew sharply to $544.8 million, up 73% year over year, bu...
Hims & Hers Health, Inc. (HIMS) Q2 2025 Earnings Call Transcript
Seeking Alpha
Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Andrew Dudum - Co-Founder, Chairman & CEO Bill Newby - Head of Investor Relations Oluyemi Okupe - Chief Financial Officer Conference Call Participants Brian Gil Tanquilut - Jefferies...
Hims & Hers: Buy The Earnings Dip, Slowly (Rating Downgrade)
Seeking Alpha
Despite a Q2 revenue miss and cash flow inflection into negative territory, Hims & Hers' long-term growth prospects remain intact due to ongoing platform broadening and international expansion. Management's ambitious vision, new C-suite hires, and $1B in fresh capital support aggressive growth plans...
Hims & Hers: Buy The Core Engine, Not The Headline
Seeking Alpha
Hims & Hers Health's Q2 revenue miss and decelerating growth triggered a stock drop, but core business ex-GLP-1 remains robust with strong subscriber growth. Profitability is improving, with adjusted EBITDA nearly doubling year-over-year and higher average revenue per subscriber offsetting margin pr...
What's Next For HIMS Stock?
Forbes
Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong growth but did not meet revenue forecasts. The company disclosed revenue of $544.8 million, which reflects a strong 73% increase compared to the previous year, although it did...
Hims & Hers shares fall on mixed Q2 report, light revenue forecast
Proactive Investors
Hims & Hers (NYSE:HIMS) shares fell 12% before US markets opened on Tuesday as the company posted mixed results for the second quarter and issued cautious guidance. The company reported revenue of $544.8 million, up 73% year-over-year, but short of Wall Street estimates of $552 million.
Wall Street sets HIMS' stock price for the next 12 months
Finbold
As telehealth company Hims & Hers Health (NYSE: HIMS) navigates a turbulent short-term period following a disappointing Q2 2025 earnings report, some on Wall Street are projecting extended losses for the stock.
Henry Schein Stock Falls on Q2 Earnings Miss, Revenues Top
Zacks Investment Research
HSIC slides after Q2 EPS misses estimates by 6.8%. Revenues beat with 3.2% growth and strength across key segments.
Hims & Hers falls as declining subscriber base weighs on revenue
Reuters
Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment as well as the sexual health business.
MSFT & META CapEx Good for ORCL, HIMS Sells & PFE Rallies on Earnings
Schwab Network
Marley Kayden takes investors through the morning's biggest movers, which included Hims & Hers (HIMS) sliding more than 10% after its earnings. Its revenue miss led to the selling action despite the company expanding its footprint overseas.
Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analys...
Benzinga
Shares of Hims & Hers Health Inc HIMS are under pressure Tuesday, after the company reported downbeat second-quarter revenues.
Why Did Hims & Hers Stock Crash and Then Recover After Earnings?
The Motley Fool
In this video, I will go over Hims & Hers' (HIMS -3.25%) latest earnings report and explain why the stock reacted the way it did. Watch the short video to learn more, consider subscribing, and click the special offer link below.
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged T...
GlobeNewsWire
LOS ANGELES, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”...
Hims & Hers drops on revenue miss
CNBC Television
CNBC's Brandon Gomez joins 'Squawk on the Street' to discuss the latest earnings from Hims & Hers.
Why Hims & Hers Health Stock Just Dropped
The Motley Fool
Hims & Hers Health (HIMS -6.11%), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling today, down 6.7% through 10:55 a.m. ET after missing in its second-quarter earnings report last night, on both the top and bottom lines.
Weighing HIMS GLP-1 Trends, NVO Partnership & Other Businesses
Schwab Network
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily on its GLP-1 drugs sales.
HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down
Zacks Investment Research
Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and subscriber growth.
Wait Out The GLP-1 Storm - Buy The Hims And Hers Post-Earnings Dip
Seeking Alpha
Hims and Hers faced a short-term revenue dip due to regulatory changes and GLP-1 customer offboarding, but core growth remains strong. Subscriber numbers surged 31% quarter-over-quarter, and product diversification continues to drive long-term revenue expansion. Regulatory-driven shipment cadence ch...
Shareholders of Hims & Hers Health, Inc. Should Contact Levi & Korsinsky Before...
GlobeNewsWire
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit.
Show All Sources
Related Posts
Other News
Back to Top